🚨Judge Reed O'Connor STRIKES DOWN a major provision of the Affordable Care Act requiring insurers to cover a vast amount of preventive care cost-free (contraception, cancer screening, PrEP, a ton of pregnancy-related care). The ruling applies nationwide. storage.courtlistener.com/recap/gov.usco…

Clonal hematopoiesis is an expansion of blood stem cell clones caused by mutations in a recurrent set of genes. Our paper on factors mediating expansion of these mutant clones is published today. nature.com/articles/s4158… Thread below...

I've said "ship has sailed" & results justify adjuv osi. However, IMO, you/we should give less 👏📣& openly acknowledge major, systematic ethical/scientific probs that compromise if not undermine ADAURA interpretation. We shouldn't just REWARD cheating that HARMS pts on ctrl arm.

Thrilled to share our latest work out today nature . A collaborative effort with many great, super smart colleagues, especially Gabe Griffin volker hovestadt 🧬 Peter van Galen : nature.com/articles/s4158…

Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with all kinds of bad outcomes, like risk of heart disease, stroke, liver disease, lung disease, and blood cancers. We wondered if CHIP had any association to AD.

I'm excited to share a new paper and, with it, my first #tweetorial. Out today in Journal of Adolescent Health, this brief report with Dr. Jacquelyn Stephens (she/her), Emma Adam, and colleagues offers 3 insights about a sample of late adolescents followed for a 5-year period. cc: Northwestern SESP #newpaperalert 1/X

Among hospitalized adults, the risk of acute kidney injury did not differ between cefepime and piperacillin-tazobactam, but neurological dysfunction was more common with cefepime. #IDWeek2023 ja.ma/3RYQHSD

This is video of said event on the sideline, going through the cadence with the line, before Dobbs goes into the game. Unreal.

Just out in JAMA Network Open, we analyze use of terms that minimize toxicity in myeloma trials. Thanks to a stellar team led by Mimi Najjar, MD, with Raj Chakraborty Eddie Cliff David Steensma, MD Aaron Goodman - “Papa Heme” Samer Al Hadidi, MD,MS,FACP Kate / Myeloma Amateur tinyurl.com/3hfm28sw #mmsm 🧵1/

Did you ever wonder why our marrow is located inside of our *bones*, #MedTwitter? There’s no a priori anatomical reason it should be sited there. Blood cells could form in our spleens & livers, as they do during our fetal lives; or elsewhere, as in some animals. Let’s discuss! /1

Meet the longest lasting project of the lab⏳ 🦴 marrow fat cells provide local fuel for hematopoietic stem cells after MI 🔥 rdcu.be/dsN4e Very happy that it is now out in Nature Cardiovascular Research ❤️ Thank you fellows and collaborators for hanging in there on this journey!

#ASH23 Excellent talk from Michael Savona describing Alex Silver wonderful PhD work which delineates differences in the biology and clinical outcomes between distinct DNMT3A variants. Going to be hard to justify lumping all DNMT3A mutations as one entity in CHIP going forward

Matt Jenkins from Ferrell Lab with the most popular poster describing his work on TET2 and monocyte inflammation in CH. #ASH23

⭐️THRILLED to host this meeting w/ my good friend Dr. Cathy Eng in beautiful Nashville. Join us as we have the LEADING thought leaders discuss the latest data including a special appearance by the Oncology Brothers Register here👇 web.cvent.com/event/c61fd6dd… Dr. Cathy Eng David R. Spigel, MD, FASCO

It was great to see everyone who attended our MPN-MDS US Focus Meeting last week! Our 5th annual meeting was better than ever with great presentations and debates all moving forward the future of treatment options for patients. Thank you to the wonderful co-chairs,

🔥 Tune in to our new episode on maintenance therapy in #MultipleMyeloma with Hira Mian & Manni Mohyuddin ! We discuss a wide range of RCTs from CALGB to FORTE, ideal endpoints for maintenance trials, and role of MRD! tinyurl.com/4mtjyz6m Here is clip on Dara maint. in CASSIOPEIA!

Informative paper in Blood Journal re achievement of CRh with targeted therapies in AML! ashpublications.org/blood/article/…

It's out! Jackie Bader led our new The Mark Foundation for Cancer Research Endeavor team study showing obesity promotes PD-1 on macrophages to suppress anti-tumor immunity but sensitize to checkpoint therapy--a new mechanism of the cancer "obesity paradox" VUMC_VCI Vanderbilt-Ingram Cancer Center nature.com/articles/s4158…

Our latest research on the Risk of Incident Cytopenia in Clonal Hematopoiesis is live on medRxiv! We leveraged data from 3 biobanks AllofUsResearch UK Biobank & BioVU (Vanderbilt Health biobank) to investigate how #CHIP drives cytopenia & subsequent progression to myeloid

🎉Excited to present our latest work out today nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN? nature.com/articles/s4158…